Page 9 - Biocon

Biocon Biologics announces top leadership appointments including COO

Biocon Biologics Ltd on Friday announced key leadership appointments, including those of Rhonda Duffy as Chief Operating Officer (COO) and Sandeep Athalye as Chief Development Officer. The company, a subsidiary of Biocon Ltd also announced the appointment of David Gibson as its Global Head - Business Development to lead all licensing, strategic partnering and business development activities. He joins the company from GlaxoSmithKline (GSK). Duffy will lead manufacturing, quality and supply chain management. She brings over 30 years of experience in the global pharmaceuticals industry, the company said in a statement. On the other hand, Athalye, who has been with Biocon Biologics for over six years as its Chief Medical Officer, has been elevated to Chief Development Officer to head CMC, clinical development and medical and regulatory affairs, it added. "These new additions to the leadership team bring rich, global experience which will help prepare the organisation for the future and

Biocon Biologics gets positive opinion from EMA for ophthalmology product

Yesafili aims to treat various visual impairments and age-related macular degeneration

Biocon Biologics eyes third of FY24 revenue from emerging markets

BBL, which launched Hulio, a biosimilars version of Abbvie's blockbuster drug Humira, in the US earlier this week, is planning to launch this drug in other countries in the near term

Biocon Biologics expands to over 70 countries, enters emerging markets

Completes integration of the acquired biosimilars business from Viatris

Stelis sells Bengaluru facility to Biocon arm Syngene for Rs 702 cr

Strides's 37 per cent stake in Stelis is valued at Rs 800 cr

F&O Strategy for Biocon: HDFC Securities recommends a Bull Spread

The stock price of Biocon has broken out on the daily chart with higher volumes where it closed at highest level since June 7, 2023

API manufacturing facility in Bangalore receives GMP certificate: Biocon

Shares of Biocon, on Thursday, fell nearly 1% at Rs 241.40 on BSE

Biocon IPO after integration of Viatris market: MD & CEO Shreehas Tambe

'From our perspective, we have operated with a high band and a lower band model'

Biocon shares trim most of early gains, end flat amid profit-taking

Shares of Biocon trimmed most of their early gains and ended flat on Wednesday amid profit-taking. During the early trade, the stock climbed nearly 8 per cent after the biotechnology major's consolidated net profit increased 31 per cent for the March quarter. The stock gained 7.12 per cent to Rs 259.50 during the day on the BSE but failed to hold on to the momentum and ended flat. It settled at Rs 243 apiece, marginally up 0.31 pe cent. On the NSE, the stock settled at Rs 242.95 per share, a gain of 0.33 per cent after rallying 7.61 per cent to Rs 260.60 during the day. In volume terms, 18.97 lakh shares of the company were traded on the BSE and over 1.77 crore shares on the NSE during the day. On Tuesday, Biocon said its consolidated net profit increased 31 per cent to Rs 313 crore for the March quarter on the back of robust sales. The company had reported a net profit of Rs 239 crore in January-March 2021-22. Total revenue increased to Rs 3,929 crore in the fourth quarter as a

Stocks to Watch today, May 24: Adani Group, Max Health, Biocon, Manyavar

Stocks to watch on May 24, 2023: Cummins, Hindalco, India Cements, LIC, National Aluminium, Nykaa and Oil India among prominent companies scheduled to announce Q4 results on Wednesday.

Competition Commission gives nod to Edelweiss-Biocon Biologics deal

Fair-trade regulator CCI on Tuesday said it has cleared Edelweiss Alternative Asset Advisors and ESOF III Investment Fund's subscription to certain compulsorily convertible debentures of Biocon Biologics Ltd. The deal has been cleared under the green channel route. Edelweiss Alternative Asset Advisors is a Sebi-registered alternative asset advisor, while ESOF III Investment Fund is a Sebi-registered Alternative Investment Fund (AIF). The proposed combination relates to Edelweiss Alternative Asset Advisors and ESOF III Investment Fund's proposal to subscribe to certain compulsorily convertible debentures issued by Biocon Biologics Ltd (BBL), according to CCI. BBL is a global biosimilar firm, engaged in the manufacturing and commercialisation of pharmaceutical formulations. The Competition Commission of India (CCI) said it has approved the proposed deal. "The parties' activities do not exhibit any horizontal, vertical, or complementary overlaps in any of the plausible relevant ...

Biocon Biologics facility gets EU GMP certification for Bevacizumab

Biotechnology major Biocon on Friday said the Bengaluru-based plant of Biocon Biologics has received EU GMP approval for a biosimilar product. Biocon Biologics' facility has received a certificate of GMP compliance for Bevacizumab from the representative European inspection authority -- Health Products Regulatory Authority (HPRA), Ireland. Bevacizumab is indicated for the treatment of various types of cancers and a specific eye disease. "This approval reflects Biocon Biologics compliance with the highest international regulatory standards and enables the company to continue addressing the needs of patients in the EU," a company spokesperson said in a statement. This (B3) facility, which is one of India's largest monoclonal antibodies (mAbs) manufacturing facilities, had received the EU GMP Certification for manufacturing biosimilar Trastuzumab last year, the spokesperson said. Biocon Biologics is a subsidiary of Biocon Ltd.

Serum Institute of India doubles Biocon investment to $300 million

The earlier investment by SILS in BBL was at a valuation of $4.9 billion, and the fresh $150-million investment pushes it up at $6 billion

Serum Institute to pump in additional $150 mn in Biocon Biologics

Serum Institute of Life Sciences will invest an additional USD 150 million in Biocon Biologics as the partners decided to restructure the deal which was inked in 2021, Biocon said on Tuesday. With the fresh capital infusion, Serum's total investment in Biocon Biologics will touch USD 300 million. Biocon Biologics Limited (BBL) and Serum Institute of Life Sciences (SILS) have reached an agreement to withdraw from the original equity structure contemplated under their strategic alliance announced in September, 2021, the Bengaluru-based biotechnology firm said in a statement. As per the new terms of the collaboration, Serum Life Sciences, a part of vaccine major Serum Institute of India, would make an additional equity investment of USD 150 million through the conversion of the USD 150 million loan provided to Biocon Pharma Ltd, a wholly-owned subsidiary of Biocon Ltd, into equity in BBL, it noted. This investment is in addition to the USD 150 million that Serum Institute of Life ...

Serum Institute to double its investment in Biocon's unit to $300 million

SILS will now make an additional equity investment of $150 million through the conversion of an earlier loan provided to Biocon Pharma into equity in BBL

Integrated Core Strategies (Asia) buys Biocon shares worth Rs 185 crore

Integrated Core Strategies (Asia) Pte on Tuesday bought shares of biopharmaceutical company Biocon for Rs 185 crore through an open market transaction. According to the bulk deal data available with the National Stock Exchange (NSE), Integrated Core Strategies (Asia) Pte purchased 80,61,599 shares at an average price of Rs 229.26 each share. The aggregate deal value is Rs 184.82 crore. Details about the sellers could not be immediately ascertained. On Tuesday, shares of Biocon closed marginally lower at Rs 229.50 apiece on NSE.

Have to keep R&D spends at 12% of revenue: Biocon's Kiran Mazumdar-Shaw

It's a high growth phase for us in Biocon Biologics: We crossed the Rs 1,500-crore mark in revenue for the first time this quarter. We will exit this year (FY23) at Rs 2,000-crore level

Viatris deal-related expenses drag Biocon's Q3 net into Rs 42 cr loss

This, even as revenues rise 36% and Ebitda is up 35%

Biocon sells 9.96% stake in contract research firm Syngene via open market

Bengaluru-based Biocon had in September 2022 sold a 5.4% stake in the open market, as per an exchange filing

Bank of Baroda, CG Power may get added to MSCI global standard index

Biocon is expected to get excluded from the index